Showing results (141-150 of 186) with videos related to
Sort By:
Pageof 19
Cancer Genomics & Proteomics|April 28, 2017
Prognostic Evaluation of Epidermal Growth Factor Receptor (EGFR) Genotype and Phenotype Parameters in Triple-negative Breast CancersSofia Levva, Vassiliki Kotoula, Ioannis Kostopoulos, et al.Oncotarget|October 28, 2015
Tumors with high-density tumor infiltrating lymphocytes constitute a favorable entity in breast cancer: a pooled analysis of four prospective adjuvant trialsVassiliki Kotoula, Kyriakos Chatzopoulos, Sotiris Lakis, et al.Cancer Genomics & Proteomics|October 30, 2019
Genotyping KRAS and EGFR Mutations in Greek Patients With Non-small-cell Lung Cancer: Incidence, Significance and Implications for TreatmentHelena Linardou, Vassiliki Kotoula, George Kouvatseas, et al.Cancer Medicine|September 22, 2018
Evaluation of the prognostic value of CD3, CD8, and FOXP3 mRNA expression in early-stage breast cancer patients treated with anthracycline-based adjuvant chemotherapyMarinos Tsiatas, Konstantine T Kalogeras, Kyriaki Manousou, et al.Clinical Colorectal Cancer|August 13, 2019
Angiogenic and Antiangiogenic VEGFA Splice Variants in Colorectal Cancer: Prospective Retrospective Cohort Study in Patients Treated With Irinotecan-Based Chemotherapy and BevacizumabGeorge Pentheroudakis, Leonidas Mavroeidis, Kyriaki Papadopoulou, et al.Journal of Translational Medicine|January 14, 2012
HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapyGeorge Fountzilas, Christos Valavanis, Vassiliki Kotoula, et al.Breast Cancer Research and Treatment|March 22, 2012
Prevalence of BRCA1 mutations among 403 women with triple-negative breast cancer: implications for genetic screening selection criteria: a Hellenic Cooperative Oncology Group StudyFlorentia Fostira, Marianthi Tsitlaidou, Christos Papadimitriou, et al.BMC Cancer|July 4, 2012
XELIRI-bevacizumab versus FOLFIRI-bevacizumab as first-line treatment in patients with metastatic colorectal cancer: a Hellenic Cooperative Oncology Group phase III trial with collateral biomarker analysisDimitrios Pectasides, George Papaxoinis, Konstantine T Kalogeras, et al.Breast Cancer Research and Treatment|March 16, 2006
Evaluation of the prognostic value of HER-2 and VEGF in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapyIoannis Kostopoulos, Petroula Arapantoni-Dadioti, Helen Gogas, et al.BMC Cancer|February 5, 2013
Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypesGeorge Pentheroudakis, Vassiliki Kotoula, Wendy De Roock, et al.Pageof 19